Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
F 32.73 -4.16% -1.42
REPL closed down 4.16 percent on Wednesday, March 3, 2021, on 1.13 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down
Historical REPL trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
200 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -4.16%
Slingshot Bearish Bearish Swing Setup -7.59%
Narrow Range Bar Range Contraction -7.59%
NR7 Range Contraction -7.59%
Oversold Stochastic Weakness -7.59%
Oversold Stochastic Weakness -5.49%
Older End-of-Day Signals for REPL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 17 hours ago
200 DMA Support about 17 hours ago
Down 5% about 18 hours ago
Down 3% about 18 hours ago
Down 2 % about 18 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Immune System Immunotherapy Cancer Treatments Virotherapy Immunotherapy Product Experimental Cancer Treatments Oncolytic Virus Rp1 Transgene Sa

Is REPL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 54.85
52 Week Low 8.58
Average Volume 432,747
200-Day Moving Average 32.05
50-Day Moving Average 39.74
20-Day Moving Average 37.37
10-Day Moving Average 35.38
Average True Range 2.53
ADX 25.8
+DI 12.32
-DI 32.25
Chandelier Exit (Long, 3 ATRs ) 37.97
Chandelier Exit (Short, 3 ATRs ) 39.57
Upper Bollinger Band 43.00
Lower Bollinger Band 31.74
Percent B (%b) 0.09
BandWidth 30.12
MACD Line -1.87
MACD Signal Line -1.58
MACD Histogram -0.2986
Fundamentals Value
Market Cap 1.5 Billion
Num Shares 46 Million
EPS -1.01
Price-to-Earnings (P/E) Ratio -32.28
Price-to-Sales 0.00
Price-to-Book 7.94
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.35
Resistance 3 (R3) 36.50 35.45 35.74
Resistance 2 (R2) 35.45 34.53 35.37 35.54
Resistance 1 (R1) 34.09 33.96 33.57 33.94 35.34
Pivot Point 33.04 33.04 32.78 32.96 33.04
Support 1 (S1) 31.68 32.12 31.16 31.53 30.12
Support 2 (S2) 30.63 31.55 30.55 29.92
Support 3 (S3) 29.27 30.63 29.72
Support 4 (S4) 29.12